Noveris Health Sciences Inc. MYCOF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 483.80K | 230.60K | 3.60K | -51.20K | 175.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 507.50K | 230.60K | 3.60K | -80.40K | 173.80K |
| Operating Income | -507.50K | -230.60K | -3.60K | 80.40K | -173.80K |
| Income Before Tax | 16.50K | -1.18M | 2.27M | 53.60K | -9.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.50K | -1.18M | 2.27M | 53.60K | -9.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.50K | -1.18M | 2.27M | 53.60K | -9.40K |
| EBIT | -507.50K | -230.60K | -3.60K | 80.40K | -173.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | -0.07 | 1.83 | 0.04 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.05 | -0.15 | 0.03 | -0.05 |
| EPS Diluted | 0.00 | -0.07 | 1.83 | 0.04 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.05 | -0.15 | 0.03 | -0.05 |
| Average Basic Shares Outstanding | 58.55M | 15.87M | 1.24M | 1.24M | 1.24M |
| Average Diluted Shares Outstanding | 58.55M | 15.87M | 1.24M | 1.24M | 1.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |